D. Faries

发表

A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results

J. Johnston, S. Robinson, T. Kennedy-Martin, 2015, Trials.

Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.

M. Swartz, H. Ascher-Svanum, D. Faries, 2006, The Journal of clinical psychiatry.

The cost of relapse and the predictors of relapse in the treatment of schizophrenia

R. Conley, H. Ascher-Svanum, D. Salkever, 2010, BMC psychiatry.

A TWO-STAGE DOSE SELECTION STRATEGY IN PHASE I TRIALS WITH WIDE DOSE RANGES

O. Wang, D. Faries, O. Wang, 2000, Journal of biopharmaceutical statistics.

Practical modifications of the continual reassessment method for phase I cancer clinical trials.

D. Faries, D Faries, 1994, Journal of biopharmaceutical statistics.

When Doubly Robust Methods Meet Machine Learning for Estimating Treatment Effects from Real-World Data: A Comparative Study

Shu Yang, I. Lipkovich, Z. Kadziola, 2022, 2204.10969.

Addressing unmeasured confounding in comparative observational research

Xiang Zhang, James D Stamey, G. Imbens, 2018, Pharmacoepidemiology and drug safety.

Alternative Weighting Approaches For Matching Adjusted Indirect Comparisons (Maic)

Z. Kadziola, D. Faries, A. Brnabic, 2015 .

Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary

K. Anstrom, G. Stone, E. Peterson, 2016, Journal of the American Heart Association.

Digital Tracking of Rheumatoid Arthritis Longitudinally (DIGITAL) Using Biosensor and Patient-Reported Outcome Data: Protocol for a Real-World Study

J. Curtis, D. Faries, J. Poon, 2019, JMIR research protocols.

PMH19: DIFFERENCES AMONG ANTIPSYCHOTICS IN THE TIME TO ALL-CAUSE DRUG DISCONTINUATION: RESULTS FROM A LONGITUDINAL NATURALISTIC STUDY OF SCHIZOPHRENIA

M. Swartz, H. Ascher-Svanum, D. Faries, 2003 .

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.

H. Ascher-Svanum, B. Kinon, S. Tunis, 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

PE1 ASSESSING EFFECTIVENESS IN THE PRESENCE OF TREATMENT SWITCHING: DATA FROM AN EFFECTIVENESS STUDY OF ANTIPSYCHOTICS

S. Tunis, D. Faries, A. Nyhuis, 2004 .

Calculating responder days for cost-effectiveness studies

D. Faries, M. Stensland, A. Nyhuis, 2003, Schizophrenia Research.

Abuse liability assessment of atomoxetine in a drug-abusing population.

Rodney J. Moore, D. Jasinski, A. Allen, 2008, Drug and alcohol dependence.

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia

R. Conley, K. Schuh, H. Ascher-Svanum, 2011, ClinicoEconomics and outcomes research : CEOR.

Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States.

M. Stokes, C. Earle, K. Lang, 2009, Lung cancer.

Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life – A Case Study of the Innovative Medicines Initiative

J. Johnston, K. Abrams, M. Happich, 2020, Clinical pharmacology and therapeutics.

Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study

R. Burge, T. Sugihara, S. Nojiri, 2013, Journal of osteoporosis.

Excess costs associated with misdiagnosis of Alzheimer's disease among U.S. Medicare beneficiaries with vascular dementia or Parkinson's disease

H. Birnbaum, D. Faries, U. Desai, 2013, Alzheimer's & Dementia.

Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetine

W. Shen, D. Faries, S. Able, 2013, Journal of medical economics.

When Doubly Robust Methods Meet Machine Learning for Estimating Treatment Effects from Real-World Data: A Comparative Study

Shu Yang, I. Lipkovich, Z. Kadziola, 2022, 2204.10969.

Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia

H. Ascher-Svanum, D. Faries, Baojin Zhu, 2009, BMC Research Notes.

Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE‐ACS) Study

J. Messenger, E. Peterson, M. Effron, 2016, Journal of the American Heart Association.

The effects of fluoxetine on symptoms of insomnia in depressed patients.

D. Faries, W. Satterlee, 1995, Psychopharmacology bulletin.

Predicting Response to Bolus Insulin Therapy in Patients With Type 2 Diabetes.

D. Faries, B. Benneyworth, E. Meadows, 2022, Journal of diabetes science and technology.

Moxonidine versus placebo as an aid in smoking cessation

L. Levine, D. Faries, P. Wennike, 2000, Human psychopharmacology.

A Randomized, Double-Blind Study of Continuation Treatment for Attention-Deficit/Hyperactivity Disorder After 1 Year

J. Buitelaar, J. Biederman, T. Spencer, 2007, Biological Psychiatry.

The Double-Blind Variable Placebo Lead-in Period: Results From Two Antidepressant Clinical Trials

G. Tollefson, W. Potter, D. Faries, 2001, Journal of clinical psychopharmacology.

Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study.

J. Buitelaar, J. Biederman, T. Spencer, 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

Comparative Effectiveness of Dexamethasone in Hospitalized COVID-19 Patients in the United States

A. Koch, K. Meyers, D. Faries, 2022, Advances in Therapy.

TCT-53 Assessment of 30-Day Rehospitalization For Acute Myocardial Infarction In Patients With Acute Coronary Syndrome Who Received Percutaneous Coronary Intervention: A Comparative Effectiveness Study Of Clopidogrel And Prasugrel

Zhenxiang Zhao, J. Bae, D. Faries, 2012 .

Comparing symptom response among antipsychotic medications in CATIE.

J. Rabinowitz, S. Levine, H. Ascher-Svanum, 2012, Journal of clinical psychopharmacology.

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation

L. Matza, D. Revicki, D. Naber, 2012, Patient preference and adherence.

Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study.

M. Tohen, H. Ascher-Svanum, B. Kinon, 2008, The Journal of clinical psychiatry.

Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.

S. Marder, H. Ascher-Svanum, Lizheng Shi, 2007, Psychiatric services.

Cost of antipsychotic polypharmacy in the treatment of schizophrenia

C. Correll, J. Kane, H. Ascher-Svanum, 2008, BMC psychiatry.

Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine

C. Alatorre, D. Faries, A. Nyhuis, 2018, Current medical research and opinion.

Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.

J. Biederman, K. Schuh, R. Dittmann, 2002, Pediatrics.

Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases

Bernice G Gershenson, H. Yamanaka, J. Askling, 2022, Rheumatology and Therapy.

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

C. Correll, H. Ascher-Svanum, D. Faries, 2005, BMC psychiatry.

A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia.

Christian R. Dolder, H. Ascher-Svanum, J. Lacro, 2006, The Journal of clinical psychiatry.

Cardiovascular Effects of Atomoxetine in Children, Adolescents, and Adults

J. Wernicke, D. Faries, D. Michelson, 2003, Drug safety.

The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder--Child Version: psychometric properties of an adaptive change instrument.

K. Schuh, D. Faries, K. Saylor, 2007, Journal of child and adolescent psychopharmacology.

Emotional Expression in Children Treated With ADHD Medication

C. Kratochvil, A. Perwien, D. Faries, 2008, Journal of attention disorders.

A first step towards best practice recommendations for the design and statistical analyses of pragmatic clinical trials: A modified Delphi approach

D. Torgerson, A. Troxel, T. V. van Staa, 2022, British journal of clinical pharmacology.

Causal analyses with target trial emulation for real-world evidence removed large self-inflicted biases: Systematic bias assessment of ovarian cancer treatment effectiveness.

U. Siebert, N. Mühlberger, C. Marth, 2022, Journal of clinical epidemiology.

Analysis of Observational Health Care Data Using SAS

Douglas E. Faries, Andrew Leon, Josep Haro, 2010 .

QT Correction Methods in Children and Adolescents

J. Wernicke, D. Girod, D. Faries, 2005, Journal of cardiovascular electrophysiology.

Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders.

J. Fawcett, G. Tollefson, G. Winokur, 1993, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Analysis of Treatment Effectiveness in Longitudinal Observational Data

Douglas Faries, Haya Ascher-Svanum, Mark Belger, 2007, Journal of biopharmaceutical statistics.

A comparison of reweighting estimators of average treatment effects in real world populations

Eloise E Kaizar, D. Faries, Chen-Yen Lin, 2021, Pharmaceutical statistics.

M. Stokes, K. Knopf, J. Lipscomb, 2009, Journal of managed care pharmacy : JMCP.

Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States

Zhenxiang Zhao, M. Effron, J. Bae, 2014, Current medical research and opinion.

Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States.

M. Stokes, C. Earle, D. Thompson, 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study

H. Ascher-Svanum, D. Faries, D. Milton, 2011, BMC psychiatry.

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

J. Biederman, T. Spencer, W. Potter, 2002, The Journal of clinical psychiatry.

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.

J. Wernicke, T. Spencer, F. Sallee, 2001, Pediatrics.

A Case Study of an Adaptive Clinical Trial in the Treatment of Out-Patients with Depressive Disorder

Douglas E. Faries, Roy N. Tamura, R. Tamura, 1994 .

Evaluation of Suicidalitv During Pharmacolonic Treatmeit of Mgod and NonmoGd Disorders

J. Fawcett, G. Tollefson, G. Winokur, 1993 .

Validation of the ADHD Rating Scale as a clirlician administered and scored instrument

D. Faries, J. Heiligenstein, I. Yalcin, 2001 .

The responsiveness of the Hamilton Depression Rating Scale.

D DeBrota, M. Demitrack, W. Potter, 2000, Journal of psychiatric research.

Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users.

G. Badger, W. Bickel, S. Higgins, 2002, Drug and alcohol dependence.

Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia.

S. Marder, H. Ascher-Svanum, Lizheng Shi, 2008, Psychiatric services.

Predicting psychiatric hospital admission among adults with schizophrenia.

M. Olfson, S. Marcus, H. Ascher-Svanum, 2011, Psychiatric services.

A Bayesian approach to correct for unmeasured or semi-unmeasured confounding in survival data using multiple validation data sets

Wei Shen, James D. Stamey, Xiang Zhang, 2017, Epidemiology, Biostatistics, and Public Health.

Bayesian modeling of cost‐effectiveness studies with unmeasured confounding: a simulation study

Douglas Faries, John W Seaman, James D Stamey, 2014, Pharmaceutical statistics.

Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison

C. Alatorre, H. Upadhyaya, D. Faries, 2013, Applied Health Economics and Health Policy.

An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder.

S. Faraone, J. Biederman, T. Spencer, 2001, Journal of child and adolescent psychopharmacology.

Improvement in Health-Related Quality of Life in Children with ADHD: An Analysis of Placebo Controlled Studies of Atomoxetine

C. Kratochvil, A. Perwien, A. Allen, 2004, Journal of developmental and behavioral pediatrics : JDBP.

Causal inference of hazard ratio based on propensity score matching

Shu Yang, D. Faries, Z. Cui, 2019, 1911.12430.

Predictors of switching antipsychotic medications in the treatment of schizophrenia

H. Ascher-Svanum, B. Kinon, D. Faries, 2010, BMC psychiatry.

Emotional expression during attention-deficit/hyperactivity disorders treatment: initial assessment of treatment effects.

C. Kratochvil, A. Perwien, D. Faries, 2007, Journal of child and adolescent psychopharmacology.

Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes?

T. Spencer, Ronald T. Brown, C. Kratochvil, 2006, Journal of child and adolescent psychopharmacology.

Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment

Yixin Fang, Richard C. Zink, Benjamin A. Goldstein, 2021, Statistics in Biopharmaceutical Research.

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia

M. Swartz, H. Ascher-Svanum, D. Faries, 2006, BMC psychiatry.

Pre-study feasibility and identifying sensitivity analyses for protocol pre-specification in comparative effectiveness research.

P. Ryan, D. Faries, C. Girman, 2014, Journal of comparative effectiveness research.

Covariates of depression and high utilizers of healthcare: Impact on resource use and costs.

J. Stephenson, D. Faries, R. Robinson, 2016, Journal of psychosomatic research.

Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?

C. Earle, K. Clements, K. Lang, 2010, Chemotherapy research and practice.

Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting

R. Bergenstal, D. Faries, Q. Li, 2012, Diabetes, obesity & metabolism.

Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia

L. Matza, D. Revicki, D. Naber, 2012, Psychiatry Research.

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives

K. Schuh, D. Naber, R. Keefe, 2010, Current medical research and opinion.

Treatment Discontinuation Following Randomization to Open-Label Olanzapine, Risperidone or Typical Antipsychotics During a One-Year Treatment for Schizophrenia

H. Ascher-Svanum, B. Kinon, D. Faries, 2008 .

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia

H. Ascher-Svanum, B. Kinon, D. Faries, 2010, BMC psychiatry.

Simple options for improving signal detection in antidepressant clinical trials.

M. Detke, C. Mallinckrodt, D. Faries, 2007, Psychopharmacology bulletin.

The problem of measurement error in multisite clinical trials.

D DeBrota, M. Demitrack, W. Potter, 1998, Psychopharmacology bulletin.

Long-term Evaluation of Opioid Treatment in Fibromyalgia

David A. Williams, K. Kroenke, P. Mease, 2015, The Clinical journal of pain.

Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorder

D. Faries, S. Able, S. Gelwicks, 2010, International clinical psychopharmacology.

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia

R. Baker, H. Ascher-Svanum, A. Shekhar, 2007, Schizophrenia bulletin.

The Effectiveness of a Private Orthopaedic Practice-Based Osteoporosis Management Service to Reduce the Risk of Subsequent Fractures

A. Araujo, O. Baser, Clifford B. Jones, 2018, The Journal of bone and joint surgery. American volume.

The burden of depressive symptoms in the long-term treatment of patients with schizophrenia

R. Conley, H. Ascher-Svanum, B. Kinon, 2007, Schizophrenia Research.

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use.

H. Ascher-Svanum, B. Kinon, S. Tunis, 2006, Journal of clinical psychopharmacology.

The 3-year clinical and functional course of schizophrenia among individuals with and without diabetes at study entry.

H. Ascher-Svanum, D. Faries, F. Ernst, 2007, Primary care companion to the Journal of clinical psychiatry.

Medical costs of Alzheimer's disease misdiagnosis among US Medicare beneficiaries

H. Birnbaum, D. Faries, U. Desai, 2015, Alzheimer's & Dementia.

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients

H. Ascher-Svanum, D. Faries, P. Haddad, 2009, BMC psychiatry.

Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study

R. Lipton, A. Araujo, R. Shapiro, 2022, Headache.

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.

P. Weiden, H. Ascher-Svanum, B. Kinon, 2014, Clinical schizophrenia & related psychoses.

Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the reflections study.

David A. Williams, K. Kroenke, P. Mease, 2013, Pain medicine.

Predictors of duloxetine adherence and persistence in patients with fibromyalgia

D. Faries, D. Novick, Z. Cui, 2012, Journal of pain research.

The importance of unresolved fatigue in depression: costs and comorbidities.

J. Stephenson, D. Faries, E. Dennehy, 2015, Psychosomatics.

Impact of non-remission of depression on costs and resource utilization: from the COmorbidities and symptoms of DEpression (CODE) study

L. Marangell, J. Stephenson, D. Faries, 2015, Current medical research and opinion.

Treatment response trajectories and antipsychotic medications: Examination of up to 18months of treatment in the CATIE chronic schizophrenia trial

J. Rabinowitz, S. Levine, H. Ascher-Svanum, 2012, Schizophrenia Research.

PCV8 Assessment of 30-Day Rehospitalization for Acute Myocardial Infarction in Patients with Acute Coronary Syndrome Who Received Percutaneous Coronary Intervention: A Comparative Effectiveness Study of Clopidogrel and Prasugrel

Zhenxiang Zhao, D. Faries, F. Ernst, 2012 .

Abstract 211: A Comparison of Bleeding in Patients Treated with Clopidogrel or Prasugrel in a US Hospital Database

Zhenxiang Zhao, J. Bae, D. Faries, 2012 .

Structural nested models

S. Murphy, D. Almirall, J. Haro, 2010 .

Comparing time to onset of response in antidepressant clinical trials using the cure model and the Cramer-von Mises test.

R. Tamura, D. Faries, J. Feng, 2000, Statistics in medicine.

Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment

V. Pérez, E. Alvarez, F. Artigas, 1997, The Lancet.

Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel.

Zhenxiang Zhao, M. Effron, J. Bae, 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo.

G. Tollefson, D. Faries, J. Heiligenstein, 1994, Journal of affective disorders.

Detecting Treatment Emergent Adverse Events in Clinical Trials

J. Wernicke, D. Faries, D. Milton, 2005, Drug safety.

Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study

D. Faries, Jenny Xu, H. Detke, 2015, BMC Psychiatry.

Atomoxetine in the Management of Children with ADHD: Effects on Quality of Life and School Functioning

Ronald T. Brown, C. Kratochvil, A. Perwien, 2006, Clinical pediatrics.

Propensity score matching and subclassification in observational studies with multi‐level treatments

Shu Yang, Zbigniew Kadziola, G. Imbens, 2015, Biometrics.

An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia*

B. Kinon, S. Tunis, D. Faries, 2007, Current medical research and opinion.

Reweighting estimators to extend the external validity of clinical trials: methodological considerations

Eloise E Kaizar, D. Faries, J. Johnston, 2023, Journal of biopharmaceutical statistics.

Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder

D. Faries, Xianchen Liu, Yi Chen, 2011, ClinicoEconomics and outcomes research : CEOR.

Atomoxetine in the treatment of children with ADHD: A randomized, placebo-controlled dose-response study

J. Wernicke, T. Spencer, D. Faries, 2001, European Neuropsychopharmacology.

A double‐blind trial of fluoxetine, 20 mg, and placebo in out‐patients with DSM‐III-R major depression and melancholia

G. Tollefson, D. Faries, J. Heiligenstein, 1993, International clinical psychopharmacology.

Direct Medical Costs and Medication Compliance among Fibromyalgia Patients: Duloxetine Initiators vs. Pregabalin Initiators

D. Faries, P. Sun, D. Novick, 2014, Pain practice : the official journal of World Institute of Pain.

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy

J. Kane, H. Ascher-Svanum, B. Kinon, 2011, ClinicoEconomics and outcomes research : CEOR.

Practical recommendations on double score matching for estimating causal effects

Shu Yang, I. Lipkovich, Z. Kadziola, 2021, Statistics in medicine.

Application and comparison of generalized propensity score matching versus pairwise propensity score matching.

R. Goodloe, D. Faries, L. Hess, 2018, Journal of comparative effectiveness research.

Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients

A. Rush, H. Roffwarg, D. Dunner, 1994, Psychiatry Research.

A randomized play-the-winner design for multi-arm clinical trials

D. Faries, John S. Andersen, J. Andersen, 1994 .

PDI-4A: An Augmented Provisional Screening Instrument Assessing 5 Additional Common Anxiety-Related Diagnoses in Adult Primary Care Patients

J. Davidson, P. Trzepacz, K. Kroenke, 2011, Postgraduate medicine.

Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia

H. Ascher-Svanum, B. Kinon, D. Faries, 2007, Patient preference and adherence.

Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL)

L. Matza, J. Johnston, D. Faries, 2007, Quality of Life Research.

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia

H. Ascher-Svanum, D. Faries, F. Ernst, 2004, Annals of general hospital psychiatry.

Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions.

N. Dreyer, D. Faries, K. Sheffield, 2020, Journal of comparative effectiveness research.

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia

Christian R. Dolder, H. Ascher-Svanum, J. Lacro, 2008, Patient preference and adherence.

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

M. Witte, H. Ascher-Svanum, D. Faries, 2011, European Psychiatry.

A provisional screening instrument for four common mental disorders in adult primary care patients.

P. Trzepacz, K. Kroenke, L. Adler, 2011, Psychosomatics.

PMH51 THE COST-EFFECTIVENESS OF EARLY RESPONDERS VERSUS EARLY NON-RESPONDERS TO ATYPICAL ANTIPSYCHOTIC THERAPY

J. Kane, H. Ascher-Svanum, B. Kinon, 2010 .

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

H. Ascher-Svanum, B. Kinon, D. Faries, 2009, BMC psychiatry.

Cost Effectiveness and Resource Allocation Open Access Methodological Issues in Assessing Changes in Costs Pre-and Post-medication Switch: a Schizophrenia Study Example

H. Ascher-Svanum, D. Faries, A. Nyhuis, 2022 .

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

H. Ascher-Svanum, B. Kinon, D. Faries, 2008, Current medical research and opinion.

Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective

D. Faries, D. Novick, Z. Cui, 2012, Journal of medical economics.

P.1.078 Pindolol augments the antidepressant efficacy of fluoxetine. Results of a double-blind, controlled trial

V. Pérez, F. Artigas, D. Faries, 1996, European Neuropsychopharmacology.

Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine

D. Faries, D. Novick, Z. Cui, 2011, Journal of medical economics.

Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective.

D. Faries, L. Niu, B. Johnstone, 2011, Clinical therapeutics.

Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention.

K. Anstrom, E. Peterson, L. Mauri, 2016, JAMA cardiology.

“A Bayesian sensitivity analysis to evaluate the impact of unmeasured confounding with external data: a real world comparative effectiveness study in osteoporosis”

J. Seaman, D. Faries, N. Boytsov, 2016, Pharmacoepidemiology and drug safety.

Association of blood glucose levels with in-hospital mortality and 30-day readmission in patients undergoing invasive cardiovascular surgery

B. Nathanson, B. Bode, Sherry A. Martin, 2012, Current medical research and opinion.

Estimating optimal treatment regimes via subgroup identification in randomized control trials and observational studies

Haoda Fu, H. Fu, D. Faries, 2016, Statistics in medicine.

Digital Tracking of Rheumatoid Arthritis Longitudinally (DIGITAL) Using Biosensor and Patient-Reported Outcome Data: Protocol for a Real-World Study (Preprint)

J. Curtis, D. Faries, J. Poon, 2019 .

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example

H. Ascher-Svanum, D. Faries, A. Nyhuis, 2009 .

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial

H. Ascher-Svanum, B. Kinon, T. Sugihara, 2012, BMC Medical Research Methodology.

Inclusion Of Multiple Studies In Matching Adjusted Indirect Comparisons (Maic)

Alan Brnabic, Douglas E. Faries, Mark Belger, 2015 .

Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study

J. Rabinowitz, S. Levine, H. Ascher-Svanum, 2011, Schizophrenia Research.

Characteristics and Use Patterns of Patients Taking First-Generation Depot Antipsychotics or Oral Antipsychotics for Schizophrenia

S. Marder, H. Ascher-Svanum, Lizheng Shi, 2007 .

Evaluating the impact of unmeasured confounding with internal validation data: an example cost evaluation in type 2 diabetes.

Karen Price, John W. Seaman, Douglas Faries, 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Evaluating bias control strategies in observational studies using frequentist model averaging

D. Madigan, I. Lipkovich, Z. Kadziola, 2022, Journal of biopharmaceutical statistics.

Integrating Randomized Placebo-Controlled Trial Data with External Controls: A Semiparametric Approach with Selective Borrowing

Shu Yang, I. Lipkovich, D. Faries, 2023, 2306.16642.

A Simulation-Based Evaluation of Statistical Methods for Hybrid Real-World Control Arms in Clinical Trials

Xiang Zhang, D. Faries, K. Sheffield, 2022, Statistics in Biosciences.

The challenges of evaluating dose response in flexible‐dose trials using marginal structural models

I. Lipkovich, C. Mallinckrodt, D. Faries, 2012, Pharmaceutical statistics.

Costs of treating patients with schizophrenia who have illness-related crisis events

H. Ascher-Svanum, D. Salkever, D. Faries, 2008, BMC psychiatry.

Evaluating dose response from flexible dose clinical trials

I. Lipkovich, D. Baron, C. Mallinckrodt, 2008, BMC psychiatry.